Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

XOMA:GR

3.269 EUR 0.062 1.86%

As of 15:02:44 ET on 03/26/2015.

Snapshot for XOMA Corp (XOMA)

Open: 3.442 Day's Range: 3.199 - 3.442 Volume: 1,132
Previous Close: 3.331 52wk Range: 2.436 - 4.664 1-Yr Rtn: -14.06%

Stock Chart for XOMA

No chart data available.
  • XOMA:GR 3.203
  • 1D
  • 1M
  • 1Y
3.331
Interactive XOMA Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for XOMA

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.5730
Est. PEG Ratio -
Market Cap (M EUR) 379.81
Shares Outstanding (M) 116.19
30 Day Average Volume 843
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for XOMA

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for XOMA

XOMA Corporation is a biopharmaceutical company that develops and manufactures genetically engineered protein, peptide, and antibody pharmaceuticals. The Company's medical targets include bacterial and fungal infections, infectious complications, and immunologic and inflammatory disorders. XOMA's primary drug development platform is bactericidal/permeability-increasing protein.

John VarianChief Executive OfficerThomas Burns "Tom"VP:Finance
Patrick J ScannonExec VP/Chief Scientific Ofcr/FounderPaul D RubinSenior VP:Research & Dev
More Company Profile & Key Executives for XOMA

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil